Neurodegeneration

Neurodegenerative disorders such as Alzheimer's and Parkinson's disease are characterized by progressive protein dysregulation, including aggregation, synaptic dysfunction, impaired proteostasis, neuroinflammation, and region-specific neuronal vulnerability. Proteomics enables molecular characterization across distinct brain tissues, cerebrospinal fluid, and plasma, supporting biomarker discovery and disease monitoring. CSF proteomics provides direct access to CNS-associated changes, while plasma profiling offers scalable, minimally invasive assessment across disease stages. Region-resolved tissue proteomics can identify spatially distinct molecular signatures linked to selective degeneration and disease spread. Low-input workflows are essential for precious clinical material, and longitudinal proteomic analysis can capture progression, therapeutic response, and circulating readouts of central pathology. Together, these approaches support mechanistic studies and translational biomarker development in neurodegeneration.